➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Harvard Business School
Merck
Mallinckrodt
Express Scripts

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Icosabutate


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Icosabutate?

Icosabutate is an investigational drug.

There have been 5 clinical trials for Icosabutate. The most recent clinical trial was a Phase 1 trial, which was initiated on July 17th 2019.

The most common disease conditions in clinical trials are Fatty Liver, Dyslipidemias, and Non-alcoholic Fatty Liver Disease. The leading clinical trial sponsors are Pronova BioPharma, NorthSea Therapeutics B.V., and [disabled in preview].

There are seven US patents protecting this investigational drug and one hundred and six international patents.

Recent Clinical Trials for Icosabutate
TitleSponsorPhase
A Phase 2b Study of Icosabutate in Nonalcoholic Steatohepatitis (NASH)NorthSea Therapeutics B.V.Phase 2
A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) IntervalNorthSea Therapeutics B.V.Phase 1
Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy SubjectsPronova BioPharmaPhase 1

See all Icosabutate clinical trials

Clinical Trial Summary for Icosabutate

Top disease conditions for Icosabutate
Top clinical trial sponsors for Icosabutate

See all Icosabutate clinical trials

US Patents for Icosabutate

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Icosabutate   Get Started Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started Free
Icosabutate   Get Started Free Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN)   Get Started Free
Icosabutate   Get Started Free Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN)   Get Started Free
Icosabutate   Get Started Free Substituted fatty acids for treating non-alcoholic steatohepatitis BASF AS (Oslo, NO)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Icosabutate

Drugname Country Document Number Estimated Expiration Related US Patent
Icosabutate Australia AU2017261372 2036-05-05   Get Started Free
Icosabutate Canada CA3023278 2036-05-05   Get Started Free
Icosabutate China CN107847398 2036-05-05   Get Started Free
Icosabutate European Patent Office EP3452003 2036-05-05   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Moodys
AstraZeneca
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.